Newest studies

Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease

55/100 ✓ Peer-reviewed Genetics Cell reports

Key finding: Combining network-based prediction and retrospective case-control observations with 10 million individuals, we identified that usage of four drugs (ibuprofen, gemfibrozil, cholecalciferol, and ceftriaxone) is associated with reduced likelihood of AD incidence. +1 more finding

• Genetics
• Treatments
• Digital Tools

Full summary, score breakdown and related studies → Original source

Right Brain: Oriented to Self

32/100 ✓ Peer-reviewed Risk factors Neurology

Key finding: While clinically useful, the MSE often neglects to capture a person's individuality. +4 more findings

Full summary, score breakdown and related studies → Original source

Lecanemab in Early Alzheimer's Disease

80/100 ✓ Peer-reviewed Treatments The New England journal of medicine

Key finding: The mean CDR-SB score at baseline was approximately 3.2 in both groups. +1 more finding

• Treatments
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample

66/100 ✓ Peer-reviewed Biomarkers Neurology

Key finding: Blood biomarkers showed significant longitudinal changes corresponding to cognitive decline, clinical AD, and structural MRI characteristics. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review

41/100 ✓ Peer-reviewed Tau biomarkers Diagnostics (Basel, Switzerland)

Key finding: The main pathophysiological theory is based on a vicious circle of disruption in circulation of cerebrospinal fluid (CSF) that leads to the deceleration of its absorption. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology

60/100 ✓ Peer-reviewed TREM2 and immune genetics Nature aging

Key finding: Here, we measured the microglial marker soluble TREM2 and the disease-associated microglial activation stage 2 markers AXL, MERTK, GAS6, LPL, CST7, SPP1 and CSF1 in nondemented individuals from the Swedish BioFINDER-2 cohort who underwent longitudinal tau-positron emission tomography (PET), amyloid-PET and global cognitive assessment. +3 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae

50/100 ✓ Peer-reviewed Biomarkers Nature communications

Key finding: We find that Aβ deposition increases linearly until it reaches an apparent plateau at a late age, while Aβ seeding activity increases more rapidly and reaches a plateau earlier, coinciding with the onset of a robust increase of CSF NfL. +4 more findings

• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

Personal social networks of people with Down syndrome

36/100 ✓ Peer-reviewed Down syndrome and Alzheimer's American journal of medical genetics. Part A

Key finding: Studies in the neurotypical population have demonstrated that personal social networks can mitigate cognitive decline and the development of Alzheimer disease. +1 more finding

• Down Syndrome

Full summary, score breakdown and related studies → Original source

The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators

45/100 ✓ Peer-reviewed Inflammation and the immune system Bioorganic chemistry

Key finding: The clinical trials of Aβ monoclonal antibody drugs have almost failed, giving rise to great attention on the other etiologic hypothesis regarding AD such as metal ions dysmetabolism and chronic neuroinflammation. +3 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Plasma p-tau181/Aβ1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ1-42 and future cognitive decline

48/100 ✓ Peer-reviewed Tau biomarkers Alzheimer's & dementia (Amsterdam, Netherlands)

Key finding: The p-tau181/Aβ 1-42 ratio showed the best prediction of Aβ-PET across all participants (area under the curve [AUC] = 0.905, 95% confidence interval [CI]: 0.86-0.95) and in CN (AUC = 0.873; 0.80-0.94), and symptomatic (AUC = 0.908; 0.82-1.00) adults. +2 more findings

• Biomarkers
• Brain Scans
• Brain Biology

Full summary, score breakdown and related studies → Original source

Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice

41/100 ✓ Peer-reviewed Drug development Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Key finding: Growing evidence demonstrated that tau pathology in AD spreads in a prion-like manner. +4 more findings

• Brain Biology
• Treatments

Full summary, score breakdown and related studies → Original source

The Effect of E-commerce on Grocery Store Choice and Retail Competition

26/100 ✓ Peer-reviewed Risk factors Not indexed

Key finding: E-commerce continues its expansion, and most retail groups have opened online distribution channels in the French grocery market. +3 more findings

Full summary, score breakdown and related studies → Original source

Research attitudes in families of individuals with Down syndrome: importance for clinical trials

41/100 ✓ Peer-reviewed Down syndrome and Alzheimer's Alzheimer's research & therapy

Key finding: This is one of the first formal studies to evaluate research attitudes among relatives of individuals with DS and shows the feasibility of using this approach to answer important questions that will guide trialists developing treatments for AD in DS.

• Down Syndrome
• Clinical Trials

Full summary, score breakdown and related studies → Original source

A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia

50/100 ✓ Peer-reviewed Clinical trials Aging medicine (Milton (N.S.W))

Key finding: Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. +4 more findings

• Clinical Trials

Full summary, score breakdown and related studies → Original source

Predictors of Documented Goals-of-Care Discussion for Hospitalized Patients With Chronic Illness

60/100 ✓ Peer-reviewed End-of-life care Journal of pain and symptom management

Key finding: Among hospitalized patients with serious illness, documented goals-of-care discussions identified by NLP were more common among patients with older age and increased burden of acute or chronic illness, and less common among racially or ethnically minoritized patients.

• Care Services
• Health Equity

Full summary, score breakdown and related studies → Original source

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

79/100 ✓ Peer-reviewed Clinical trials Translational psychiatry

Key finding: Significant treatment effects were observed after removing outliers (KarXT n = 54, placebo n = 63; p = 0.04). +2 more findings

• Clinical Trials

Full summary, score breakdown and related studies → Original source

A Potential Link Between Visceral Obesity and Risk of Alzheimer's Disease

40/100 ✓ Peer-reviewed Disease mechanisms Neurochemical research

Key finding: Visceral obesity (VO) is usually associated with low-grade inflammation due to higher expression of pro-inflammatory cytokines by adipose tissue. +3 more findings

• Brain Biology
• Risk Factors

Full summary, score breakdown and related studies → Original source

Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease

68/100 ✓ Peer-reviewed Caregiving Nature genetics

Key finding: Next to variants in TREM2, SORL1 and ABCA7, we observed a significant association of rare, predicted damaging variants in ATP8B4 and ABCA1 with AD risk, and a suggestive signal in ADAM10. +2 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Gut microbiota-derived metabolites and their importance in neurological disorders

41/100 ✓ Peer-reviewed Disease mechanisms Molecular biology reports

Key finding: Depending on the levels of specific metabolites produced in the host, it can exert beneficial or detrimental effects on the brain and have been linked to several neurodegenerative and neuropsychiatric disorders. +4 more findings

Full summary, score breakdown and related studies → Original source

Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy

41/100 ✓ Peer-reviewed Drug development International immunopharmacology

Key finding: Tubulin-associated unit (tau) has been associated with more than 25 neurological disorders-the so-called tauopathies. +1 more finding

• Treatments
• Brain Biology

Full summary, score breakdown and related studies → Original source

Com-mens: a home-based logopaedic intervention program for communication problems between people with dementia and their caregivers - a single-group mixed-methods pilot study

37/100 ✓ Peer-reviewed Health systems and care delivery International journal of language & communication disorders

Key finding: Repeated measures analyses revealed no significant changes over time. +1 more finding

• Caregiving

Full summary, score breakdown and related studies → Original source

Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020

69/100 ✓ Peer-reviewed Health systems and care delivery JAMA Network Open

Key finding: There were 21 603 to 51 236 patients per year (total for 2010-2020, 381 488 patients) in the OAC-eligible incident AF cohort (mean [SD] age, 77.2 [6.1] to 77.4 [6.8] years; 13 871 [51.8%] to 22 901 [49.8%] women). +4 more findings

Full summary, score breakdown and related studies → Original source

Association between hearing loss and development of dementia using formal behavioural audiometric testing within the Mayo Clinic Study of Aging (MCSA): a prospective population-based study

48/100 ✓ Peer-reviewed Digital health tools The lancet. Healthy longevity

Key finding: After adjusting for sex, years of education, smoking status, diabetes, hypertension, apolipoprotein E ε4 carriership, and hearing rehabilitation (defined as hearing aid or cochlear implant use), neither PTA (hazard ratio [HR] per 10-decibels hearing level increase of 0·99 (95% CI 0·89-1·12; p=0·91) nor WRS (HR per 10% decrease of 0·98, 95% CI 0·89-1 ·07; p=0·65) was significantly associated with the development of dementia. +2 more findings

• Risk Factors

Full summary, score breakdown and related studies → Original source

Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer's disease progression and heterogeneity

60/100 ✓ Peer-reviewed Digital health tools Science advances

Key finding: In an advanced machine learning analysis of postmortem brain and in vivo blood multi-omics molecular data ( N = 1863), we integrated epigenomic, transcriptomic, proteomic, and metabolomic profiles into a multilevel biological AD taxonomy. +4 more findings

Full summary, score breakdown and related studies → Original source

Longitudinal associations between sleep duration and cognitive impairment in Chinese elderly

57/100 ✓ Peer-reviewed Risk factors Frontiers in aging neuroscience

Key finding: The empirical study showed a U-shaped relationship between sleep duration and increased risk of cognitive impairment. +4 more findings

• Lifestyle

Full summary, score breakdown and related studies → Original source